MA38541A1 - Facteurs de transcription artificiels génétiquement modifiés pour pallier le piégeage endosomique - Google Patents
Facteurs de transcription artificiels génétiquement modifiés pour pallier le piégeage endosomiqueInfo
- Publication number
- MA38541A1 MA38541A1 MA38541A MA38541A MA38541A1 MA 38541 A1 MA38541 A1 MA 38541A1 MA 38541 A MA38541 A MA 38541A MA 38541 A MA38541 A MA 38541A MA 38541 A1 MA38541 A1 MA 38541A1
- Authority
- MA
- Morocco
- Prior art keywords
- artificial transcription
- genetically modified
- transcription factors
- protein
- zinc finger
- Prior art date
Links
- 102000040945 Transcription factor Human genes 0.000 title abstract 4
- 108091023040 Transcription factor Proteins 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 101710185494 Zinc finger protein Proteins 0.000 abstract 2
- 102100023597 Zinc finger protein 816 Human genes 0.000 abstract 2
- 230000026683 transduction Effects 0.000 abstract 2
- 238000010361 transduction Methods 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000001163 endosome Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000030648 nucleus localization Effects 0.000 abstract 1
- 108020001580 protein domains Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne un facteur de transcription artificiel comprenant une protéine à doigt de zinc polydactyle ciblant spécifiquement un promoteur de gène, génétiquement modifié pour pallier le piégeage endosomique après transduction dans des cellules. Un tel facteur de transcription artificiel comprend une protéine à doigt de zinc polydactyle, condensée à un domaine de protéine d'inhibition ou d'activation, une séquence de localisation nucléaire, un domaine de transduction de protéine, et un site de reconnaissance de protéase spécifique à l'endosome. Ces facteurs de transcription artificiels transductibles sont particulièrement utiles pour le traitement de maladies provoquées ou modulées par des protéines réceptrices liées à la membrane, des protéines réceptrices nucléaires ou des produits de gènes haplo-insuffisants.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13162197 | 2013-04-03 | ||
| PCT/EP2014/056589 WO2014161880A1 (fr) | 2013-04-03 | 2014-04-02 | Facteurs de transcription artificiels génétiquement modifiés pour pallier le piégeage endosomique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38541A1 true MA38541A1 (fr) | 2017-02-28 |
Family
ID=48044672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38541A MA38541A1 (fr) | 2013-04-03 | 2015-10-21 | Facteurs de transcription artificiels génétiquement modifiés pour pallier le piégeage endosomique |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20160046682A1 (fr) |
| EP (1) | EP2981547A1 (fr) |
| JP (1) | JP2016515595A (fr) |
| KR (1) | KR20160002880A (fr) |
| CN (1) | CN105339386A (fr) |
| AR (1) | AR095982A1 (fr) |
| AU (1) | AU2014247130A1 (fr) |
| BR (1) | BR112015025283A2 (fr) |
| CA (1) | CA2908455A1 (fr) |
| EA (1) | EA201591593A1 (fr) |
| MA (1) | MA38541A1 (fr) |
| MX (1) | MX2015014021A (fr) |
| PH (1) | PH12015502421A1 (fr) |
| SG (1) | SG11201508057VA (fr) |
| TN (1) | TN2015000437A1 (fr) |
| TW (1) | TW201514202A (fr) |
| WO (1) | WO2014161880A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016050934A1 (fr) * | 2014-10-02 | 2016-04-07 | Aliophtha Ag | Démêlage endosomal de facteurs de transcription artificiels |
| US11371023B2 (en) | 2016-11-22 | 2022-06-28 | Wisconsin Alumni Research Foundation | Artificial transcription factors and uses thereof |
| CN106987599B (zh) * | 2017-03-28 | 2021-06-11 | 重庆医科大学 | 一种抑制人bcr-abl融合基因表达或导致人bcr-abl基因功能丧失的锌指核酸酶及其应用 |
| CN107632160B (zh) * | 2017-08-30 | 2019-04-30 | 福建师范大学 | Celsr3蛋白在制备肝癌术后预后评估试剂盒中的应用、肝癌预后评估试剂盒及方法 |
| CN110108887B (zh) * | 2019-05-05 | 2022-01-28 | 深港产学研基地（北京大学香港科技大学深圳研修院） | Mff在心衰中的应用 |
| JP2022532236A (ja) * | 2019-05-16 | 2022-07-13 | トラスティーズ オブ ボストン ユニバーシティ | 調節された合成遺伝子発現システム |
| CN112695052A (zh) * | 2020-12-25 | 2021-04-23 | 华南农业大学 | 一种重组人糖皮质激素受体GRα-His蛋白及其表达和纯化方法 |
| CN113499335B (zh) * | 2021-07-13 | 2023-06-20 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向自噬融合治疗神经退行性疾病的药物 |
| WO2023028598A1 (fr) * | 2021-08-26 | 2023-03-02 | Donald Danforth Plant Science Center | Modification de la résistance aux maladies par édition épigénomique |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005003315A2 (fr) | 2003-07-01 | 2005-01-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Compositions et methodes pour la transfection assistee par peptide |
| WO2008063113A1 (fr) | 2006-11-20 | 2008-05-29 | Cepep Iii Ab | Peptides de pénétration cellulaire et construction les contenant constitués de 15 à 25 acides aminés de la protéine de suppression tumorale p14arf ou p19arf |
| WO2010056808A2 (fr) * | 2008-11-12 | 2010-05-20 | The Regents Of The University Of California | Compositions et procédés pour reprogrammer et redifférencier des cellules |
| KR101095841B1 (ko) | 2009-02-19 | 2011-12-21 | 주식회사 나이벡 | 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도 |
-
2014
- 2014-04-01 AR ARP140101460A patent/AR095982A1/es unknown
- 2014-04-01 TW TW103112114A patent/TW201514202A/zh unknown
- 2014-04-02 EA EA201591593A patent/EA201591593A1/ru unknown
- 2014-04-02 WO PCT/EP2014/056589 patent/WO2014161880A1/fr active Application Filing
- 2014-04-02 US US14/781,701 patent/US20160046682A1/en not_active Abandoned
- 2014-04-02 BR BR112015025283A patent/BR112015025283A2/pt not_active Application Discontinuation
- 2014-04-02 SG SG11201508057VA patent/SG11201508057VA/en unknown
- 2014-04-02 JP JP2016505804A patent/JP2016515595A/ja active Pending
- 2014-04-02 EP EP14714289.7A patent/EP2981547A1/fr not_active Withdrawn
- 2014-04-02 CN CN201480031910.4A patent/CN105339386A/zh active Pending
- 2014-04-02 CA CA2908455A patent/CA2908455A1/fr not_active Abandoned
- 2014-04-02 AU AU2014247130A patent/AU2014247130A1/en not_active Abandoned
- 2014-04-02 MX MX2015014021A patent/MX2015014021A/es unknown
- 2014-04-02 KR KR1020157031592A patent/KR20160002880A/ko not_active Application Discontinuation
-
2015
- 2015-09-28 TN TN2015000437A patent/TN2015000437A1/en unknown
- 2015-10-20 PH PH12015502421A patent/PH12015502421A1/en unknown
- 2015-10-21 MA MA38541A patent/MA38541A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015025283A2 (pt) | 2017-10-10 |
| US20160046682A1 (en) | 2016-02-18 |
| JP2016515595A (ja) | 2016-05-30 |
| MX2015014021A (es) | 2016-06-24 |
| TW201514202A (zh) | 2015-04-16 |
| AU2014247130A1 (en) | 2015-10-22 |
| CA2908455A1 (fr) | 2014-10-09 |
| TN2015000437A1 (en) | 2017-01-03 |
| PH12015502421A1 (en) | 2016-02-22 |
| AR095982A1 (es) | 2015-11-25 |
| KR20160002880A (ko) | 2016-01-08 |
| WO2014161880A1 (fr) | 2014-10-09 |
| EA201591593A1 (ru) | 2016-04-29 |
| CN105339386A (zh) | 2016-02-17 |
| SG11201508057VA (en) | 2015-10-29 |
| EP2981547A1 (fr) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38541A1 (fr) | Facteurs de transcription artificiels génétiquement modifiés pour pallier le piégeage endosomique | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| MX2022006002A (es) | Proteinas de fusion inmunomoduladoras y usos de las mismas. | |
| EP3956896A4 (fr) | Génération de séquences de protéines à l'aide de techniques d'apprentissage automatique | |
| EP3939606A3 (fr) | Composés et procédés améliorés permettant de supprimer des réponses immunitaires à des agents thérapeutiques | |
| WO2015191666A3 (fr) | Fusions de raf1 | |
| SG11201806502UA (en) | Conjugate of therapeutic enzymes | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| MA34722B1 (fr) | Méthodes et compositions pour l'immunothérapie de maladies neurales | |
| UA117045C2 (uk) | Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування | |
| EA202090084A1 (ru) | Новый терапевтический ферментный слитый белок и его применение | |
| AR106556A1 (es) | Anticuerpos de un solo dominio dirigidos contra antígenos extracelulares | |
| NZ774126A (en) | Spd-1 variant - fc fusion proteins | |
| MA39347B2 (fr) | Protéines de fusion d'uti | |
| ECSP20083339A (es) | Proteínas inmunodominantes y fragmentos en esclerosis múltiple | |
| MA38543A1 (fr) | Facteurs de transcription artificiels pour le traitement de maladies provoquées par une haplo-insuffisance d'opa1 | |
| EA201790725A1 (ru) | Основанные на близости расположения способы выбора партнеров для связывания | |
| MX2018003445A (es) | Expresion de proteinas que contienen fc. | |
| BR112021026364A2 (pt) | Antígenos de câncer e métodos | |
| EP4276089A3 (fr) | Modulateurs de l'activité enzymatique de la lipoxygénase et de la cyclooxygénase | |
| NZ731491A (en) | Cd83 binding proteins and uses thereof | |
| FR3016888B1 (fr) | Synthetases de la colistine et cluster de genes correspondants | |
| MX2022002628A (es) | Proteinas de fusion y usos de las mismas. | |
| PH12014502182A1 (en) | Methods and compositions for modulating notch activity |